By: IPP Bureau
Last updated : May 26, 2023 12:10 pm
For Q4 ended FY23, company reported net profit of Rs. 12.56 crore as against net profit of Rs. 11.02 crore in the corresponding period last year
Lincoln Pharmaceuticals Limited has achieved the milestone of Rs. 533 crore Revenue and Rs.100 crore Profit before tax for the first time in a financial year. Company has reported its Best-ever results in a financial year with highest - Revenue, EBITDA and Net Profit during FY 2023.
The company reported net profit of Rs. 72.90 crore for FY23 as against net profit of Rs. 69.36 crore in the corresponding period last year, growth of 5.1 I%. Total Income for FY23 was reported at Rs. 532.79 crore, higher by I 0.52% over previous fiscal's same period total income of Rs. 482.08 crore. Company reported EBITDA of Rs. I I 1.65 crore in FY23, rise of 5.86% as compared to EBITDA of Rs. 105.47 crore in FY22. EPS for FY23 was reported at Rs. 36.40 per share.
Commenting on the results and performance, Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Limited, said, "Company has achieved the milestone of Rs. 533 crore revenue and Rs. 100 crore in Profit in FY23 with a robust a operational and financial performancealong with healthy growth in revenue, margins and profitability. We expect the growth momentum to continue and expect to get further boost in coming years. Company has set a target of achieving its margins. With a robust Rs. 750 crore revenue by FY26 while maintaining or improving its performance, the company has recommended a dividend of Rs. 1. 5 per share."
For Q4 ended FY23, company reported net profit of Rs. 12.56 crore as against net profit of Rs. 11.02 crore in the corresponding period last year, growth of 14%. Total Income for the Q4FY23 was reported at Rs. 116.41 crore, higher by 11.47% over previous fiscal's same period income of Rs. 104.4 crore. Company reported EBITDA of Rs. 20.54 crore in Q4 FY23, rise of 6.26% as compared to Rs. 19.33 crore in the corresponding period last year. EPS for Q4FY23 was at Rs. 6.27 per share.
"Company has reported its highest-ever Revenue, EBITDA and Net Profit reported on a yearly basis. Company is reporting excellent growth in the domestic and export business and expects to maintain healthy growth in years to come. Strategic growth initiatives, product and geographical expansion, and operational efficiency are likely to contribute to growth going forward, said Patel.
Update on Cephalosporin Expansion - In September 2021, the company acquired a plant in Mehsana, Gujarat to launch Cephalosporin products. The company has invested Rs. 30 crore in the cephalosporin plant - including acquisition and subsequent capacity expansion using an internal source of funds. The plant is expected to contribute sales of around Rs. 150 crore in the next 3 years. Company has received approval from WHO-GMP for Tablet Capsule, dry-powder Suspension products.